Top

Published in:

01-03-2008 | Review Article

Statin treatment for rheumatoid arthritis: a promising novel indication

Author: Kosmas I. Paraskevas

Published in: Clinical Rheumatology | Issue 3/2008

Abstract

The results of several cross-sectional trials suggest that patients with rheumatoid arthritis (RA) have increased vascular risk and cardiovascular mortality. It was demonstrated that inflammation plays a pivotal role in the pathogenesis of both RA and atherosclerosis. This association may explain the high incidence of cardiovascular disease in RA patients. A number of recent studies show that routine statin use in patients with RA offers considerable advantages. Statin treatment has been supported to exert a beneficial effect on disease activity, swollen joint count, endothelial dysfunction, and arterial stiffness in RA patients. These improvements are coupled with a mild to moderate improvement in plasma markers of inflammation, such as C-reactive protein and erythrocyte sedimentation rate. Statins have a satisfactory safety profile with relatively few adverse effects. In the absence of side effects and contraindications, it may be reasonable to consider statin use in selected cases, particularly in patients with a long history of active RA who are at increased cardiovascular risk.

Walker JG, Littlejohn GO (2006) Measuring quality of life in rheumatic conditions. Clin Rheumatol 26:671–673PubMedCrossRef

Palkonyai E, Kolarz G, Kopp M et al (2007) Depressive symptoms in early rheumatoid arthritis: a comparative longitudinal study. Clin Rheumatol 26:753–758PubMedCrossRef

Isik A, Koca SS, Ozturk A, Mermi O (2007) Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol 26:872–878PubMedCrossRef

Birtane M, Uzunca K, Tastekin N, Tuna H (2007) The evaluation of quality of life in fibromyalgia syndrome: a comparison with rheumatoid arthritis using SF-36 Health Survey. Clin Rheumatol 26:679–684PubMedCrossRef

Taal E, Bobietinska E, Lloyd J (2006) Successfully living with chronic arthritis. The role of the allied health professionals. Clin Rheumatol 25:189–197PubMedCrossRef

Brooks PM (2006) The burden of musculoskeletal disease—a global perspective. Clin Rheumatol 25:778–781PubMedCrossRef

Frostegard J (2005) Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 25:1776–1785PubMedCrossRef

Sherer Y, Shoenfeld Y (2006) Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2:99–106PubMedCrossRef

Chung CP, Avalos I, Raggi P, Stein CM (2007) Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin Rheumatol 26:1228–1233PubMedCrossRef

10.

Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis. Arthritis Rheum 46:862–873PubMedCrossRef

11.

Van Doornum S, McColl G, Jenkins A et al (2003) Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 48:72–80PubMedCrossRef

12.

Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J (2005) Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 35:8–17PubMedCrossRef

13.

Giles JT, Post W, Blumenthal RS et al (2006) Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2:320–329PubMedCrossRef

14.

Warrington KJ, Kent PD, Frye RL et al (2005) Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther 7:R984–R991PubMedCrossRef

15.

Watson DJ, Rhodes T, Guess HA (2003) All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 30:1196–1202PubMed

16.

Gazi IF, Boumpas DT, Mikhailidis DP, Ganotakis ES (2007) Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol 25:102–111PubMed

17.

Costenbader KH, Coblyn JS (2005) Statin therapy in rheumatoid arthritis. South Med J 98:534–540PubMedCrossRef

18.

Arnaud C, Mach F (2006) Potential antiinflammatory and immunomodulatory effects of statins in rheumatologic therapy. Arthritis Rheum 54:390–392PubMedCrossRef

19.

Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126PubMedCrossRef

20.

Binder CJ, Chang MK, Shaw PX et al (2002) Innate and acquired immunity in atherogenesis. Nat Med 8:1218–1226PubMedCrossRef

21.

Hansson GK, Holm J, Jonasson L (1989) Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 135:169–175PubMed

22.

Frostegard J, Ulfgren AK, Nyberg P et al (1999) Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145:33–43PubMedCrossRef

23.

Wick G, Knoflach M, Xu Q (2004) Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 22:361–403PubMedCrossRef

24.

Xu Q, Dietrich H, Steiner HJ et al (1992) Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb 12:789–799PubMed

25.

George J, Harats D, Gilburd B et al (2000) Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 102:1822–1827PubMed

26.

George J, Afek A, Gilburd B et al (1998) Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation 98:1108–1115PubMed

27.

Mach F, Schonbeck U, Sukhova GK et al (1998) Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature 394:200–203PubMedCrossRef

28.

Toubi E, Shoenfeld Y (2004) The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 37:457–464PubMedCrossRef

29.

Nicoletti A, Kaveri S, Caligiuri G et al (1998) Immunoglobulin treatment reduces atherosclerosis in Apo E knockout mice. J Clin Invest 102:910–918PubMedCrossRef

30.

Robertson AK, Rudling M, Zhou X et al (2003) Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 112:1342–1350PubMedCrossRef

31.

Solomon DH, Karlson EW, Rimm EB et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307PubMedCrossRef

32.

Arthritis Research Campaign. Arthritis: the big picture. http://www.arc.org.uk/arthinfo/bigpic.asp#6. Accessed 4 November 2007

33.

Davenport G; Primary Care Rheumatology Society Steering Committee (2004) Rheumatology and musculoskeletal medicine. Br J Gen Pract 54:457–464PubMed

34.

Wolfe F, Mitchell DM, Sibley JT et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494PubMedCrossRef

35.

Nicola PJ, Maradit-Kremers H, Roger VL et al (2005) The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 52:412–420PubMedCrossRef

36.

Snow MH, Mikuls TR (2005) Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol 17:234–241PubMedCrossRef

37.

Maradit-Kremers H, Crowson CS, Nicola PJ et al (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52:402–411PubMedCrossRef

38.

Wallberg-Jonsson S, Ohman ML, Dahlqvist SR (1997) Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 24:445–451PubMed

39.

del Rincon ID, Williams K, Stern MP et al (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737–2745PubMedCrossRef

40.

Jacobsson LT, Turesson C, Hanson RL et al (2001) Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum 44:1170–1176PubMedCrossRef

41.

Chung CP, Oeser A, Raggi P et al (2005) Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 52:3045–3053PubMedCrossRef

42.

Park YB, Ahn CW, Choi HK et al (2003) Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 46:1714–1719CrossRef

43.

Kumeda Y, Inaba M, Goto H et al (2002) Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 46:1489–1497PubMedCrossRef

44.

Daza L, Aguirre M, Jimenez M et al (2007) Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors. Clin Rheumatol 26:533–537PubMedCrossRef

45.

Nagata-Sakurai M, Inaba M, Goto H et al (2003) Inflammation and bone resorption as independent factors of accelerated arterial wall thickening in patients with rheumatoid arthritis. Arthritis Rheum 48:3061–3067PubMedCrossRef

46.

Roman MJ, Moeller E, Davis A et al (2006) Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 144:249–256PubMed

47.

Dessein PH, Joffe BI (2006) When is a patient with rheumatoid arthritis at risk for cardiovascular disease? J Rheumatol 33:201–203PubMed

48.

Cederholm A, Svenungsson E, Jensen-Urstad K et al (2005) Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 25:198–203PubMed

49.

Swanberg M, Lidman O, Padyukov L et al (2005) MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 37:486–494PubMedCrossRef

50.

Abeles AM, Pillinger MH (2006) Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy. Arthritis Rheum 54:393–407PubMedCrossRef

51.

Tristano AG, Fuller K (2006) Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved. Int Immunopharmacol 6:1833–1846PubMedCrossRef

52.

Agrawal S, Misra R, Aggarwal A (2007) Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 26:201–204PubMedCrossRef

53.

Turesson C (2004) Endothelial expression of MHC class II molecules in autoimmune disease. Curr Pharm Des 10:129–143PubMedCrossRef

54.

Palinski W, Napoli C (2002) Unraveling pleiotropic effects of statins on plaque rupture. Arterioscler Thromb Vasc Biol 22:1745–1750PubMedCrossRef

55.

Choi M, Rolle S, Rane M et al (2003) Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney Int 63:96–106PubMedCrossRef

56.

Sadeghi MM, Tiglio A, Sadigh K et al (2001) Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 71:1262–1268PubMedCrossRef

57.

Kwak B, Mulhaupt F, Veillard N et al (2001) The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 131:41–46PubMed

58.

Dolhain RJ, van der Heiden AN, ter Haar NT et al (1996) Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 39:1961–1969PubMedCrossRef

59.

Nagashima T, Okazaki H, Yudoh K et al (2006) Apoptosis of rheumatoid synovial cells by statins through the blocking of geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum 54:579–586PubMedCrossRef

60.

McCarey DW, McInnes IB, Madhok R et al (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015–2021PubMedCrossRef

61.

Hermann F, Forster A, Chenevard R et al (2005) Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 45:461–464PubMedCrossRef

62.

Ridker PM, Cushman M, Stampfer MJ et al (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–979PubMedCrossRef

63.

Ridker PM, Buring JE, Shih J et al (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731–733PubMed

64.

Koenig W, Sund M, Frohlich M et al (1999) C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99:237–242PubMed

65.

Ridker PM, Rifai N, Rose L et al (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557–1565PubMedCrossRef

66.

Pham T, Gossec L, Constantin A et al (2006) Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Jt Bone Spine 73:379–387CrossRef

67.

McInnes IB, McCarey DW, Sattar N (2004) Do statins offer therapeutic potential in inflammatory arthritis. Ann Rheum Dis 63:1535–1537PubMedCrossRef

68.

Sattar N, McInnes IB (2005) Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 17:286–292PubMedCrossRef

69.

Furberg CD, Pitt B (2001) Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2:205–207PubMedCrossRef

70.

Klareskog L, Hamsten A (2004) Statins in rheumatoid arthritis—two birds with one stone. Lancet 363:2011–2012PubMedCrossRef

71.

Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effects of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326:1423–1427PubMedCrossRef

72.

Rosenson RS (2004) Current overview of statin-induced myopathy. Am J Med 116:408–416PubMedCrossRef

73.

Kanda H, Hamasaki K, Kubo K et al (2002) Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatol 29:2024–2026PubMed

74.

Abud-Mendoza C, de la Fuente H, Cuevas-Orta E et al (2003) Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 12:607–611PubMedCrossRef

75.

Van Doornum S, McColl G, Wicks IP (2004) Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 63:1571–1575PubMedCrossRef

76.

Maki-Petaja KM, Booth AD, Hall FC et al (2007) Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 50:852–858PubMedCrossRef

77.

Okamoto H, Koizumi K, Kamitsuji S et al (2007) Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 34:964–968PubMed

78.

Tikiz C, Utuk O, Pirildar T et al (2005) Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol 32:2095–2101PubMed

79.

Charles-Schoeman C, Khanna D, Furst DE et al (2007) Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 34:1459–1464PubMed

Title: Statin treatment for rheumatoid arthritis: a promising novel indication
Author: Kosmas I. Paraskevas
Publication date: 01-03-2008
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 3/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-007-0806-8

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Statin treatment for rheumatoid arthritis: a promising novel indication

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

Chorea as a side effect of gabapentin (Neurontin®) in a patient with complex regional pain syndrome Type 1

Pedicle stress fracture: an unusual complication of pycnodysostosis

Effect of disease activity and position on autonomic nervous modulation in patients with systemic lupus erythematosus

Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein–Barr virus

Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis

Clinical and laboratory profiles of systemic lupus erythematosus associated with Sjögren syndrome in China: a study of 542 patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page